The TGF-β signaling pathway has a significant role in breast cancer initiation and promotion by regulating various cellular processes. We evaluated whether genetic variation in eight genes (TGF-β1, TGF-β2, TGF-βR1, TGF-βR2, TGF-βR3, RUNX1, RUNX2, and RUNX3) is associated with breast cancer risk in women from the Breast Cancer Health Disparities Study. A total of 3,524 cases (1,431 non-Hispanic whites (NHW); 2,093 Hispanics/Native Americans(NA)) and 4,209 population-based controls (1,599 NHWs; 2,610 Hispanics/NAs) were included in analyses. Genotypes for 47 single nucleotide polymorphisms (SNPs) were determined. Additionally, 104 ancestral informative markers estimated proportion of NA ancestry. Associations with breast cancer risk overall, by menopausal status, NA ancestry, and estrogen receptor (ER)/progesterone receptor tumor phenotype were evaluated. After adjustment for multiple comparisons, two SNPs were significantly associated with breast cancer risk: RUNX3 (rs906296 ORCG/GG = 1.15 95 % CI 1.04–1.26) and TGF-β1 (rs4803455 ORCA/AA = 0.89 95 % CI 0.81–0.98). RUNX3 (rs906296) and TGF-βR2 (rs3773644) were associated with risk in pre-menopausal women (padj = 0.002 and 0.02, respectively) and in those with intermediate to high NA ancestry (padj = 0.04 and 0.01, respectively). Self-reported race was strongly correlated with NA ancestry (r = 0.86). There was a significant interaction between NA ancestry and RUNX1 (rs7279383, padj = 0.04). Four RUNX SNPs were associated with increased risk of ER-tumors. Results provide evidence that genetic variation in TGF-β and RUNX genes are associated with breast cancer risk. This is the first report of significant associations between genetic variants in TGF-β and RUNX genes and breast cancer risk among women of NA ancestry.
reast cancer riskBreast Cancer Health Disparities StudyTGF-βsignaling pathwayNative American ancestryHispanicNon-Hispanic whiteIntroduction
The TGF-β signaling pathway includes several multifunctional cytokines and cell receptors that control the activity of particular genes to regulate cellular processes via a SMAD-mediated signaling cascade [1, 2]. Inhibition of TGF-β signaling occurs in several cancers, including breast cancer [3–5]. Genes in this pathway may play a dual role in breast cancer: as early tumor suppressors with growth-inhibitory effects, and as late promoters of invasiveness and angiogenesis [6]. Genes in the TGF-β-signaling pathway also have been linked to expression of estrogen receptors (ER) [7–10]. One study reported that absence of the TGF-β response was more likely in ER+ tumors and associated with a poor prognosis [10].
There is evidence that Runt-related transcription factors (RUNX) interact with receptor regulated SMADs (R-SMADs) and are down-stream effectors of the TGF-β signaling pathway [11]. Three RUNX family members play an important tissue-specific role in determining the fate of cells during differentiation and growth, and there is increasing evidence that loss of function is involved in carcinogenesis [12–14]. In most tumor cells, genetic variation in key members of the pathway causes resistance to the growth-inhibitory effects of TGF-β signaling [15, 16].
Despite evidence for a role of TGF-β signaling genes in breast cancer, there are sparse data for the association of variants in these genes with breast cancer risk. Studies of the associations of genetic variants in TGF-β1, TGF-β2, and TGF-β receptors (TGF-βR1, TGF-βR2, TGF-βR3) with breast cancer risk are inconsistent [5, 17–25], limited by small sample sizes [26–31], and data on non-white groups are lacking [29]. Meta-analyses, based primarily on non-Hispanic white (NHW) women, have not confirmed associations with the most commonly studied single nucleotide polymorphisms (SNPs) [TGF-β1 (rs1800469 and rs1982073) and TGF-βR1 (*6A/rs11466445)] with breast cancer risk [5, 18, 23–25], although mouse models have demonstrated that these SNPs increase (TGF-β1) and decrease (TGF-βR1) gene expression [28, 32–34]. To date, there are few, if any, published studies on the association of RUNX genes with breast cancer risk.
We investigated associations of 47 SNPs in eight genes (TGF-β1, TGF-β2, TGF-βR1, TGF-βR2, TGF-βR3, RUNX1, RUNX2, and RUNX3) with breast cancer risk in the Breast Cancer Health Disparities Study (BCHD), a population-based, collaborative study of Hispanic/Native American (NA) and NHW women living in the United States or Mexico [35]. We evaluated whether associations differ by European or NA ancestry, menopausal status, and ER and progesterone receptor (PR) tumor phenotype. Additionally, SNP–SNP interactions were assessed.
MethodsStudy population
The BCHD study is a consortium of three population-based case–control studies in the United States and Mexico: the 4-Corner’s Breast Cancer Study (4-CBCS), the San Francisco Bay Area Breast Cancer Study (SFBCS), and the Mexico Breast Cancer Study (MBCS). Participants completed an in-person interview and provided a blood or saliva sample for DNA extraction [35]. The 4-CBCS participants were between 25 and 79 years of age. Eligible cases were diagnosed with a first primary breast cancer (in situ or invasive) between 10/1999 and 05/2004 in Arizona, Colorado, New Mexico, and Utah. Controls were randomly selected and frequency-matched to cases on 5 year age distributions and ethnicity. A total of 1,850 cases (1,244 NHW; 606 Hispanic/NA) and 2,057 controls (1,329 NHW; 728 Hispanic/NA) participated. SFBCS participants were between the ages of 35 and 79 years and lived in the San Francisco Bay Area. Eligible cases were diagnosed with a first primary invasive breast cancer between 04/1995 and 04/2002 (Hispanics) or between 04/1995 and 04/1999 (NHWs); controls were selected using random-digit dialing and frequency-matched to cases on 5 year age distributions and ethnicity. A total of 1,105 cases (312 NHW; 793 Hispanic) and 1,318 controls (320 NHW; 998 Hispanic) participated. Participants from the MBCS included women between 28 and 74 years of age. Eligible cases were diagnosed with a first primary breast cancer (in situ or invasive) between 01/2004 and 12/2007 across 12 participating hospitals in three main healthcare systems. Controls were selected from the participating hospitals’ geostatistic catchment area using a probabilistic multistage design and matched to cases on 5 year age distributions, healthcare institute membership, and residency. A total of 1,881 women (850 cases, 1,031 controls) participated. All participants signed informed written consent prior to participation and the Institutional Review Board for Human Subjects at each institution approved the studies.
Data harmonization
Questionnaire data were harmonized across the three studies as previously described [35]. Women were classified as pre-menopausal or post-menopausal based on menstrual history and menopausal hormone therapy use. Women who reported still having periods were classified as pre-menopausal. Women were classified as post-menopausal if they reported natural menopause (≥12 months since last period), using hormone replacement therapy, or were at or above the 95th percentile of age for race/ethnicity of those reporting natural menopause within their study center. Mean ages for natural menopause were 58 and 56 years for 4-CBCS NHW and Hispanic/NA women, 55 and 56 years for SFBCS NHW and Hispanic women, and 54 years for MBCS Hispanic women.
Genetic data
DNA was extracted from either whole blood (n = 7,287) or saliva (n = 634) samples. Whole genome amplification (WGA) was conducted on saliva-derived DNA samples prior to genotyping. A tag-SNP approach was utilized to capture variation across candidate genes. SNPs were selected using five parameters: (1) linkage disequilibrium (LD) blocks defined using a Caucasian LD map and an r2 = 0.8; (2) minor allele frequency (MAF) > 0.1; (3) range = ±1500 base pairs (bps) from the initiation codon to the termination codon; (4) 1 SNP/LD bin; or (5) evidence of functionality. A multiplexed bead array assay based on GoldenGate chemistry (Illumina, San Diego, CA) was used for genotyping with a call rate of 99.93 % (99.65 % for saliva samples). There were 132 internal blinded replicates (1.6 % of the sample set). The duplicate concordance rate was 99.996 % as determined by 193,297 matching genotypes among sample pairs.
We investigated 47 SNPs in eight genes: TGF-β1 (2 SNPs), TGF-β2 (1 SNP), TGF-βR1 (5 SNPs), TGF-βR2 (1 SNP), TGF-βR3 (5 SNPs), RUNX1 (8 SNPs), RUNX2 (17 SNPs), and RUNX3 (8 SNPs). Supplemental Table 1 provides identification (rs) numbers and descriptions of selected SNPs. Minor allele frequencies (MAF) and Hardy-Weinberg Equilibrium (HWE) were calculated based on the frequencies of alleles and genotypes in the control population. We genotyped 104 Ancestral Informative Markers (AIMs) to characterize proportion of NA ancestry. AIMs were selected based on established differences in specific alleles between NA and European populations [36, 37].
Tumor characteristics
Statewide cancer registries in Utah, Colorado, Arizona, New Mexico, and California provided information on ER and PR tumor phenotype for a subset of 995 (69 %) NHW cases and 968 (75 %) Hispanic/NA cases. ER and PR were not available from the MBCS.
Statistical analysis
STRUCTURE 2.0 was utilized to calculate the proportion of genetic admixture based on European and NA ancestry [35, 37]. Percent ancestry was categorized, based on the distribution of NA ancestry in the control population, allowing sufficient power to assess associations of ancestral groups with breast cancer risk (≤28 %, 29–70 %,>70 %) [35]. Differences in covariates between self-reported ethnicity and case–control status were tested using the Mantel–Haenszel Chi square (χ2). Logistic regression was used to estimate odds ratios (OR) for associations of genotypes with breast cancer risk adjusting for age (<40, 40–49, 50–59, 60–69, 70+), study center (4-CBCS, SFBCS, MBCS) and percent NA ancestry. Associations for each SNP were initially assessed assuming a co-dominant mode of inheritance. Dominant and/or recessive models were considered when the trend in ORs suggested a different mode of inheritance than co-dominant and increased statistical power could be gained by collapsing genotypes. Confounding by categories of age, study center, NA ancestry, body mass index (BMI), first-degree family history of breast cancer, age at menarche, age at menopause, menopausal status, parity, age at first birth, education, oral contraceptive use, hormone therapy use, alcohol consumption, and smoking status, and for continuous measures of physical activity and NA ancestry. Covariates were considered confounders if the univariate p value was ≤0.20 and adjustment produced a change of ≥10 % in the effect estimate for the overall association of the genotype with breast cancer risk [38]. We did not observe confounding by any factor; nonetheless all models were adjusted for age, study center and percentage of NA ancestry.
Statistical interactions of SNPs with NA ancestry, self-reported ethnicity, and menopausal status were assessed using the difference in maximum likelihood estimates for logistic regression models with and without an interaction term, using a χ2 test with 2 degrees of freedom (2-df) for a co-dominant model, and 1 degree of freedom (1-df) for a dominant or recessive model. Risk of each breast cancer subtype (ER/PR tumor phenotype) was evaluated using multinomial logistic regression [39, 40]. SNP–SNP interaction models were assessed for those SNPs significantly associated with breast cancer risk and considering their biological function and potential interactions within the TGF-β signaling pathway.
P values, based on a 1-df Wald χ2 test statistic, were adjusted for multiple comparisons taking into account tag-SNPs within each gene using a step-down Bonferroni correction method [41]. This method is based on the effective number of independent SNPs determined using the SNP spectral decomposition method based on the eigenvalues of the correlation matrix among the SNPs for each gene as proposed by Nyholt [42] and modified by Li and Ji [43]. This method is conservative, especially when evaluating correlated variables such as SNPs within a gene. An adjusted P ≤ 0.05 for main effects and interactions was considered statistically significant. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
The analyses included 7,733 participants (3,524 cases, 4,209 controls) with complete data for the SNPs of interest. Approximately 60 % of participants were over 50 years of age, with a higher proportion of pre-menopausal women among Hispanic/NA cases (41 vs. 34 %) and Hispanic/NA controls (41 vs. 32 %) than NHW (p < 0.0001) (Table 1). Hispanic/NA cases tended to less educated (p <0.0001) and have more ER−/PR− tumors than NHW (23 vs. 18 %) (p = 0.001). Self-reported race/ethnicity was strongly correlated with NA ancestry (Cramer’s V, r = 0.86). Nearly all women (99.5 %) from the U.S. who self-reported being NHW were in the low NA ancestry group, whereas those who self-reported being Hispanic/NA were distributed across the intermediate (75.9 %), low (16.7 %), and high (7.4 %) NA ancestry groups. The majority of Mexico Hispanics (controls) had high (51.6 %) or intermediate (47.3 %) NA ancestry (data not shown).
Of the 47 SNPs evaluated, 10 [RUNX1 (rs7279383 and rs8127225); RUNX2 (rs10948238 and rs13201287); RUNX3 (rs906296); TGF-β1 (rs4803455); TGF-β2 (rs6604609); TGF-βR1 (rs6478974); TGF-βR2 (rs3773644); and TGF-βR3 (rs6678564)] were significantly associated with breast cancer risk after adjustment for age, study, and NA ancestry (Table 2). After adjustment for multiple comparisons, a significant increase in breast cancer risk was observed for RUNX3 (rs906296 ORCG/GG = 1.15; 95 % CI1.04–1.26; padj = 0.03) and an inverse association was observed for TGF-β1 (rs4803455, ORCC/AA = 0.89; 95 % CI 0.81–0.98; padj = 0.04). TGF-β2 (rs6604609) was significantly associated with reduced risk of breast cancer (ORTA/AA = 0.80, 95 % CI 0.71–0.91, p = 0.0002), whereas TGF-βR2 (rs3773644) was associated with increased risk of breast cancer (ORTT = 1.21, 95 % CI 1.05–1.40, p = 0.004).
RUNX3 (rs906296) had a significant interaction with menopausal status before multiple comparison adjustment (padj = 0.08), and was significantly associated with increased breast cancer risk in pre-menopausal women (ORAA = 1.33; 95 % CI 1.14–1.55 padj = 0.002) (Table 3). Although RUNX1 (rs2268288, ORCC = 1.47; 95 % CI 1.03–2.09, padj = 0.26) and RUNX3 (rs4478762, ORAA = 1.71; 95 % CI 1.04–2.82, padj = 0.21) were associated with a modest increase in post-menopausal breast cancer risk, these were not significant with adjustment for multiple comparisons. The SNPs TGF-βR2 (rs3773644, ORTT = 1.32, 95 % CI 1.04–1.68, p = 0.02) and TGF-β2 (rs6604609) (ORTA/AA = 0.77, 95 % CI 0.66–0.91, p = 0.002) were significantly associated with breast cancer risk among pre-menopausal and post-menopausal women, respectively (data not shown).
There was significant interaction between NA ancestry and RUNX1 (rs7279383, padj = 0.04) (Table 4). Women with the highest NA ancestry had a significant increase in risk (ORCG/GG = 1.75 95 % CI 1.17–2.63, padj = 0.05), whereas those with low and high NA ancestry had nonsignificant reduced risks (ORCG/GG = 0.87 95 % CI 0.76–1.00, padj = 0.41 and ORCG/GG = 0.82 95 % CI 0.69–0.97, padj = 0.14, respectively). Divergent results were also observed by NA ancestry for TGF-β1 (rs1800469); women with intermediate NA ancestry had a significant increased risk (ORTT = 1.29, 95 % CI 1.04–1.58, padj = 0.04), whereas there was a null association in those with low and high NA ancestry (ORTT = 0.96, 95 % CI 0.77–1.20, padj = 1.00, and ORTT = 0.92, 95 % CI 0.65–1.30, padj = 0.94, respectively). Several SNPs were significantly associated with increased risk in women with intermediate NA ancestry, although results were not significantly divergent across NA ancestry: RUNX3 (rs906296, ORCG/GG = 1.23, 95 % CI 1.06–1.43, padj = 0.04); and TGF-βR2 (rs3773644, ORTT = 1.44, 95 % CI 1.11–1.88, p = 0.01) (data not shown). One SNP was inversely associated with risk of women with intermediate NA ancestry: TGF-β2 (rs6604609, ORTA/AA = 0.76, 95 % CI 0.63–0.91, p = 0.003, data not shown). Further evaluation of self-reported ethnicity yielded similar results, although no significant interactions were observed.
Table 5 shows associations between TGF-β signaling SNPs and breast cancer risk stratified by ER/PR tumor phenotype. Only one SNP was significantly different across ER/PR phenotypes after adjustment for multiple comparisons (RUNX3, rs7517302, padj = 0.04). However, five SNPs were significantly associated with risk within ER/PR phenotype strata that remained significant after adjustment for multiple comparisons. RUNX1 (rs7279123) was associated with reduced breast cancer risk for ER+/PR− (padj = 0.03). There was increased breast cancer risk for ER−/PR+ (RUNX3, rs2236850, padj = 0.03); and increased risk for ER−/PR− for RUNX2 rs9463090 (padj = 0.009), RUNX2 rs12333172 (padj = 0.007) and RUNX3 rs7517302 (padj = 0.03). There were no associations between SNPs and breast cancer risk defined by ER+/PR+ phenotype. We also evaluated interactions between individual SNPs and menopausal status within ER phenotypes: no significant interactions were observed.
Lastly, SNP–SNP interactions were examined for SNPs with statistically significant main effects for breast cancer risk. Only two were statistically significant [RUNX3 (rs7517302 and rs906296)*TGF-βR1 (rs6748974)]. The combined effect for rs 7517302*rs6748974 (p = 0.003) and rs906296*rs6748974 (p = 0.02) resulted in a slight increase in risk (OR = 1.20, data not shown).
Discussion
The present analyses suggest that genetic variation in the TGF-β signaling pathway [TGF-β1, TGF-β2, TGF-βR1, TGF-βR2, TGF-βR3, RUNX1, RUNX2, and RUNX3] influences breast cancer risk in Hispanic/NA and NHW women. Four SNPs were associated with breast cancer risk [RUNX3 (rs906296); TGF-β1 (rs4803455); TGF-β2 (rs6604609); and TGF-βR2 (rs3773644)]. Additionally, associations differed by ER/PR tumor phenotype, menopausal status, and percentage NA ancestry. In particular, two SNPs, RUNX3 (rs906296) and TGF-βR2 (rs3773644) were significantly associated with increased risk in pre-menopausal women and women of intermediate NA ancestry. Additionally one SNP, TGF-β2 (rs6604609), was associated with decreased risk in these groups. This provides further evidence that RUNX3 interacts with the TGF-β signaling pathway.
Genes from the TGF-β superfamily of cytokines and RUNX family have important roles regulating cellular processes and are part of one of the most commonly altered cellular signaling pathways in cancer, making them attractive candidates for cancer-related etiology [44, 45]. A general biological mechanism for the relationship between TGF-β signaling and breast cancer may be a SMAD-mediated pathway which facilitates the transduction of signals for target genes involved in cellular processes [1]. In normal mammary cells, TGF-β1 is reported to have an anti-proliferative effect on epithelial and endothelial mammary cells by acting as a tumor suppressor down-regulating cellular growth, differentiation and apoptosis [3, 5]. Mouse models also offer evidence that increased levels of TGF-β1 in serum strengthen tumor suppressor activity, reducing risk of breast cancer [4]. Immune cells, including B-cell, T-cell, and macrophages, secrete TGF-β1, which negatively regulates their proliferation, differentiation, and activation by other cytokines. This process makes TGF-β1 an effective immunosuppressor, and disruption of the signaling pathway is linked to autoimmunity, inflammation, and cancer [46].
In most tumor cells, genetic variants can cause resistance to the inhibitory effects of TGF-β signaling [15, 16]. Exact mechanisms for resistance remain unknown, although evidence for other cancers suggests there may be decreased expression of TGF-β receptors [47, 48], oncoproteins such as p53 [49], other tumor suppressors that regulate the pathway such as RUNX3 [50], or increased expression of inhibitory SMADs (I-SMAD6 or I-SMAD-7) in the extracellular matrix [3]. There is also evidence that when TGF-β1 and TGF-βR1 are overexpressed following tumor initiation, they promote angiogenesis via cell migration and adhesion factors, resulting in metastasis [3]. RUNX genes have the ability to enhance growth regulation by making target cells sensitive to the effects of TGF-β family members. In turn, TGF-β genes can activate RUNX genes at the transcription and post-transcriptional levels [51, 52]. Most of our findings indicate that genetic variation is associated with increased breast cancer risk, suggesting that these genes are no longer acting as tumor suppressors via normal signaling.
Several epidemiological studies have investigated associations between select SNPs in TGF-β1, TGF-β2, and TGF-β receptors and breast cancer [15, 17, 18, 21, 28–32]. With the exception of one [17], most studies are underpowered and results are inconsistent. Only one study to date included Hispanic women, Le Marchand et al. [29] reported an inverse association for the (CC vs. TT) genotype of TGF-β1 (rs1982073) (ORCC = 0.81 95 % CI 0.52–1.27) in post-menopausal Hispanic women from the Multiethnic Cohort study; however, the number of Hispanic women was small (67 cases, 179 controls) and the analysis was underpowered.
Three meta-analyses were conducted for TGF-β1 (rs1800469) and breast cancer risk: no association was observed for the recessive model (TT vs. CC/CT) [18, 23, 25]. Although we did not find an overall association for the recessive model of rs1800469 also, the co-dominant model suggested increased risk for women with intermediate NA ancestry. Moreover, present study suggests there is moderate LD (r2 = 0.67) between TGF-β1 (rs1800469) and TGF-β1 (rs4803455) in both Hispanic/NA and NHW women. In our study, there was a significant inverse association of TGF-β1 (rs4803455) with breast cancer risk.
The Shanghai Breast Cancer Study [21] conducted a multistage pathway analysis evaluating 11 genes (341 SNPs) in the TGF-β signaling pathway. Results for two SNPs can be compared to those from the present study. Statistically significant results were reported for the additive model of TGF-βR1 (rs10733710, OR = 1.11, p = 0.02) and the recessive model of TGF-bR3 (rs284185, ORAA = 1.74, p = 0.004), which contrasts with our non-significant findings. The nominal p values reported by Ma et al. [21] suggest that their results may not be significant if adjusted for multiple comparisons.
Genetic variation among RUNX genes may be important in colorectal cancer [53], but there are no epidemiological data for breast cancer. We found several associations between RUNX SNPs and breast cancer risk (RUNX3 rs9062696) in women of intermediate to high NA ancestry (RUNX3 rs906296 and RUNX1 rs7279383), as well as an interaction with NA ancestry (RUNX1 rs7279383). These findings support the hypothesis that genetic variation can influence breast cancer differently in Hispanic/NA than NHW women, possibly due to unmeasured biological functional variants that influence susceptibility.
TGF-β signaling may alter expression of the estrogen receptor (ERα) and estrogen may reciprocally interfere with this signaling [7–9]. ERα activation has been reported to inhibit TGF-β1 transcription activity by up to 60 % [54, 55] and RUNX1 has been considered an “accessibility factor” for ERα binding sites [9]. RUNX2 decreases ERα mRNA and protein levels in breast cancer cells; and RUNX3 may function as a tumor suppressor by destabilizing the ERα gene and inhibiting its expression [7, 56]. Our study is the first to evaluate associations between TGF-β and RUNX genes with risk of breast cancer stratified by ER/PR tumor phenotypes. Four RUNX SNPs were significantly associated with an increased risk of ER−/PR− (RUNX2 rs9463090 and rs12333172, RUNX3 rs2236850 and rs7517302) and ER−/PR+ (RUNX1 rs7279123) tumors. These novel findings suggest that variation in RUNX genes may increase proliferation in ER− breast cells. Although the present analysis included 1,963 cases with available data on ER/PR phenotypes, tumor phenotype data for cases in MBCS were unavailable, limiting statistical power when evaluating rarer phenotypes (ER−/PR+). Nonetheless, our results support the role of these genes in influencing estrogen-related associations with breast cancer.
There are several strengths and limitations for this study. The sample size provided sufficient power to evaluate different modes of inheritance and stratified analyses. Genetic ancestry, measured by 104 AIMs markers, was used determine biological ancestry in addition to self-reported ethnicity, allowing us to focus on the biological basis of associations while evaluating lifestyle factors that differ between groups. Because of sparse data in the literature for these genes, comparisons to other studies for specific SNPs and the interpretation of our findings were guided mostly by in vivo studies. However, we used a tag-SNP approach to cover variation across the entire gene, as the selected SNPs are in linkage disequilibrium with those not reported. Finally, adjustment for multiple comparisons is conservative and may result in false negative associations.
Results from the present study may have implications for the etiology of breast cancer phenotypes and disparities between race/ethnic groups for risk. The present study is the first to report associations between variants in these genes and ER/PR tumor phenotype, menopausal status, and NA ancestry. Our results suggest that variation in these genes may explain the previously reported results that Hispanic women have increased risk of pre-menopausal, ER− breast cancer compared to NHW. Biologic significance of the genes is strongly suggested, although specific SNPs that were evaluated may or may not be functional. A better understanding of how TGF-β and RUNX genes can switch their role from tumor suppressor to promoter in breast carcinogenesis is needed, as well as how these genes may influence ER expression. Studies evaluating a larger representation of SNPs in this complex signaling pathway will aid in validating our findings.
Supplementary Material
Electronic supplementary material The online version of this article (doi:10.1007/s10549-013-2690-z) contains supplementary material, which is available to authorized users.
Acknowledgments
This research was funded in part through a Susan G. Komen training grant: Breast Cancer Disparities Epidemiology Research Training Program (KG090926) to Dr. K. Baumgartner and Dr. R. Baumgartner at the University of Louisville. The Breast Cancer Health Disparities Study was funded by Grant CA14002 from the National Cancer Institute to Dr. Slattery. The San Francisco Bay Area Breast Cancer Study was supported by Grants CA63446 and CA77305 from the National Cancer Institute, Grant DAMD17-96-1-6071 from the U.S. Department of Defense and Grant 7 PB-0068 from the California Breast Cancer Research Program. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201000036C awarded to the Cancer Prevention Institute of California; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute. The 4-Corner’s Breast Cancer Study was funded by Grants CA078682, CA078762, CA078552, and CA078802 from the National Cancer Institute. The research also was supported by the Utah Cancer Registry, which is funded by contract N01-PC-67000 from the National Cancer Institute, with additional support from the State of Utah Department of Health, the New Mexico Tumor Registry, and the Arizona and Colorado cancer registries, funded by the Centers for Disease Control and Prevention National Program of Cancer Registries and additional state support. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute or endorsement by the State of California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors. The Mexico Breast Cancer Study was funded by Consejo Nacional de Ciencia y Tecnología (CONACyT) (SALUD-2002-C01-7462). We would also like to acknowledge the contributions of the following individuals to the study: Sandra Edwards for data harmonization oversight; Erica Wolff and Michael Hoffman for laboratory support; Carolyn Ortega for her assistance with data management for the Mexico Breast Cancer Study, Jocelyn Koo for data management for the San Francisco Bay Area Breast Cancer Study, Dr. Tim Byers for his contribution to the 4-Corner’s Breast Cancer Study, and Dr. Josh Galanter for assistance in selection of AIMS markers for the study.
ReferencesShiYMassagueJMechanisms of TGF-beta signaling from cell membrane to the nucleusCell2003113668570012809600MassagueJThe transforming growth factor-beta familyAnnu Rev Cell Biol199065976412177343ElliottRLBlobeGCRole of transforming growth factor beta in human cancerJ Clin Oncol20052392078209315774796PierceDFJrMammary tumor suppression by transforming growth factor beta 1 transgene expressionProc Natl Acad Sci USA19959210425442587753792ScollenSTGF-beta signaling pathway and breast cancer susceptibilityCancer Epidemiol Biomarkers Prev20112061112111921527583ZuXTransforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an updateCell Tissue Res20123471738421845401HuangBRUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha2011New EnglandOncogeneBandAMLaihoMCrosstalk of TGF-beta and estrogen receptor signaling in breast cancerJ Mammary Gland Biol Neoplasia201116210911521390570ChimgeNOFrenkelBThe RUNX family in breast cancer: relationships with estrogen signaling2012New EnglandOncogeneBierieBAbrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancerJ Clin Invest200911961571158219451693MiyazonoKMaedaSImamuraTCoordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteinsOncogene200423244232423715156178CameronERNeilJCThe Runx genes: lineage-specific oncogenes and tumor suppressorsOncogene200423244308431415156187ItoYOncogenic potential of the RUNX gene family: ‘overview’Oncogene200423244198420815156173LundAHvan LohuizenMRUNX: a trilogy of cancer genesCancer Cell20021321321512086855LevyLHillCSAlterations in components of the TGF-beta superfamily signaling pathways in human cancerCytokine Growth Factor Rev2006171–2415816310402SerraRCrowleyMRMouse models of transforming growth factor beta impact in breast development and cancerEndocr Relat Cancer200512474976016322320CoxAA common coding variant in CASP8 is associated with breast cancer riskNat Genet200739335235817293864QiXTransforming growth factor-beta1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case-control studiesBreast Cancer Res Treat2010122127327920309626LiaoRYTGFBR1×6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controlsMol Biol Rep20103773227323219882361ColleranGThe TGFBR1×6A/9A polymorphism is not associated with differential risk of breast cancerBreast Cancer Res Treat2010119243744219390964MaXPathway analyses identify TGFBR2 as potential breast cancer susceptibility gene: results from a consortium study among AsiansCancer Epidemiol Biomarkers Prev20122171176118422539603PascheBTGFBR1×6A and cancer: a meta-analysis of 12 case-control studiesJ Clin Oncol200422475675814966109NiuWAssociation of TGFB1 −509 C > T polymorphism with breast cancer: evidence from a meta-analysis involving 23,579 subjectsBreast Cancer Res Treat2010124124324920232138WangYQAssociation between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studiesPLoS One201278e4289922905183WooSUAssociation of a TGF-beta1 gene −509 C/T polymorphism with breast cancer risk: a meta-analysisBreast Cancer Res Treat2010124248148520361250BaxterSWTransforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancerCancer Epidemiol Biomarkers Prev200211221121411867510JinQPolymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancersInt J Cancer20041121949915305380KaklamaniVGCombined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer riskCancer Res20056583454346115833881Le MarchandLT29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the multiethnic cohort studyCancer Epidemiol Biomarkers Prev200413341241515006917CoxDGTGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health StudyBMC Cancer2007717517848193HishidaATransforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese womenBreast Cancer2003101636912525765DunningAMA transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancerCancer Res200363102610261512750287PascheBConstitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPsJ Exp Clin Cancer Res2010295720500843WallaceTAMartinDNAmbsSInteractions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scaleCarcinogenesis20113281107112121464040SlatteryMGenetic variation in genes involved in hormones, inflammation, and energetic factors and breast cancer risk in an admixed population2012AustinCarcinogenesisCollins-SchrammHEMexican American ancestry-informative markers: examination of population structure and marker characteristics in European Americans, Mexican Americans Amerindians and AsiansHum Genet2004114326327114628215PritchardJKStephensMDonnellyPInference of population structure using multilocus genotype dataGenetics2000155294595910835412BursacZPurposeful selection of variables in logistic regressionSource Code Biol Med200831719087314DubinNPasternackBSRisk assessment for case-control subgroups by polychotomous logistic regressionAm J Epidemiol19861236110111173706280HosmerDJrLemeshowSSonsJWAApplied logistic regressionProbability and mathematical statistics1989New YorkWileyHolmSA simple sequentially rejective multiple test procedureScand J Stat197966570NyholtDRA simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each otherAm J Hum Genet200474476576914997420LiJJiLAdjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrixHeredity (Edinb)200595322122716077740AkhurstRJTGF beta signaling in health and diseaseNat Genet200436879079215284845MassagueJTGFbeta in CancerCell2008134221523018662538MoustakasAMechanisms of TGF-beta signaling in regulation of cell growth and differentiationImmunol Lett2002821–2859112008039LeeJDThe type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signalingCarcinogenesis201031217518319955393GobbiHTransforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasiaJ Natl Cancer Inst199991242096210110601380EwenMEp53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrestGenes Dev1995922042177851794LiQLCausal relationship between the loss of RUNX3 expression and gastric cancerCell2002109111312411955451BlythKCameronERNeilJCThe RUNX genes: gain or loss of function in cancerNat Rev Cancer20055537638715864279ItoYMiyazonoKRUNX transcription factors as key targets of TGF-beta superfamily signalingCurr Opin Genet Dev2003131434712573434SlatteryMLAssociations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of colon and rectal cancer: additional support for a TGF-beta-signaling pathwayCarcinogenesis201132331832621088106ItoIEstrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradationJ Biol Chem201028519147471475520207742MatsudaTCross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3J Biol Chem200127646429084291411555647LauQCRUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancerCancer Res200666136512652016818622
Descriptive covariates of study population, stratified by ethnicity and case–control status, Breast Cancer Health Disparities Study (n = 7,733)
Characteristic
Study populationa (n = 7,733)
pc
Non-hispanic white(n = 3,030)
Hispanic/Native American (n= 4,703)
Controls(n = 1,599)
Cases(n = 1,431)
pb
Controls(n = 2,610)
Cases(n = 2,093)
pb
N
(%)
N
(%)
N
(%)
N
(%)
Age (years)
0.04
0.22
<40
87
6.1
117
7.3
313
12.0
198
9.5
<0.0001
40–49
401
28.0
409
25.6
834
31.9
708
33.8
50–59
403
28.2
410
25.6
758
29.0
614
29.3
60–69
340
23.8
356
22.3
530
20.3
425
20.3
70+
200
13.9
307
19.2
175
6.7
148
7.1
Study
0.37
0.94
4-CBCS
1,335
83.5
1,177
82.3
736
28.2
579
27.7
<0.0001
Mexico
–
–
–
–
994
38.1
816
39.0
San Francisco
264
16.5
254
17.8
880
33.7
698
33.4
% Native american ancestry
0.21
0.0012
≤0.28
1,591
99.5
1,420
99.2
280
10.7
276
13.2
<0.0001
0.28–0.70
7
0.44
7
0.5
1,697
65.0
1,373
65.6
>0.70
1
0.1
4
0.3
633
24.3
444
21.2
Menopausal status
0.13
0.71
pre-/peri-
494
31.5
475
34.1
1,027
40.7
831
41.2
<0.0001
post-
1,075
68.5
919
65.9
1,499
59.3
1,186
58.8
Education
0.57
\0.0001
<High school
79
5.0
71
5.0
1538
60.2
1088
52.8
<0.0001
High school grad/GED
338
21.3
284
20.1
419
16.4
377
18.3
Post-high school
1,168
73.7
1,059
74.9
597
23.4
594
28.9
ER/PR status
ER+/PR+
–
–
681
68.4
–
–
–
598
61.8
–
0.001
ER+/PR−
–
–
116
11.7
–
–
117
12.1
ER−/PR+
–
–
17
1.7
–
–
28
2.9
ER−/PR−
–
–
181
18.2
–
–
225
23.2
Column percentages may not add up to 100 % due to rounding. Column totals (n) may not add up to total for each column due to missing observations: education (n = 121), menopausal status (n = 227)
Case–control status comparisons within each ethnic group, Mantel–Haenszel chi square p values reported
Ethnic group comparisons regardless of case–control status, Mantel–Haenszel chi square p values reported
TGF-β signaling pathway genes: overall associations with breast cancer risk, the breast cancer health disparities study
Gene (SNP)
Genotype
Controls (n= 4,209)
Cases (n= 3,524)
ORa
(95 % CI)
pb
N
(%)
N
(%)
RUNX1 (rs7279383)
CC
3,098
73.6
2,647
75.1
1.00
0.032 (0.23)
CG/GG
1,110
26.4
876
24.9
0.89
(0.80, 0.99)
RUNX1 (rs8127225)
TT
2,591
61.6
2,117
60.1
1.00
0.029 (0.23)
TC/CC
1,612
38.4
1,407
39.9
1.11
(1.01, 1.22)
RUNX2 (rs10948238)
CC/CT
3,602
85.6
2,950
83.8
1.00
0.028 (0.42)
TT
604
14.4
571
16.2
1.15
(1.01, 1.30)
RUNX2 (rs13201287)
GG/GA
3,899
92.6
3,226
91.5
1.00
0.050 (0.69)
AA
310
7.4
298
8.5
1.18
(1.00, 1.39)
RUNX3 (rs906296)
CC
2,701
64.2
2,143
60.8
1.00
0.004 (0.03)
CG/GG
1,505
35.8
1,379
39.2
1.15
(1.04, 1.26)
TGF-β1 (rs4803455)
CC
1,400
35.3
1,193
37.0
1.00
0.023 (0.04)
CA/AA
2,561
64.7
2,032
63.0
0.89
(0.81, 0.98)
TGF-β2 (rs6604609)c
TT
3,455
82.1
3,009
85.4
1.00
0.0002
TA/AA
753
17.9
515
14.6
0.80
(0.71, 0.91)
TGF-βR1 (rs6478974)
TT/TA
3,531
83.9
2,884
81.9
1.00
0.045 (0.19)
AA
677
16.1
639
18.1
1.13
(1.00, 1.28)
TGF-βR2 (rs3773644)c
CC/CT
3,767
89.5
3,072
87.2
1.00
0.004
TT
441
10.5
452
12.8
1.21
(1.05, 1.40)
TGF-βR3 (rs6678564)
GG
3,523
83.7
3,004
85.2
1.00
0.03 (0.11)
GC/CC
685
16.3
520
14.8
0.87
(0.77, 0.99)
Bold text designates significant associations at the 0.05 level after adjustment for multiple comparisons
Adjusted for age, study center, and genetic admixture
Wald p-value for 1 df test; p-value adjusted for multiple comparisons (Bonferroni–Holm) in parentheses
Only one SNP evaluated for each gene, multiple comparisons not applicable
The Association of TGF-β signaling pathway genes and breast cancer risk stratified by menopausal status
Gene (SNP)
Genotype
Pre/peri-menopause (n= 2,827)
Post-menopause (n =4,679)
p-intb
Controls(n = 1,306)
Cases(n = 1,521)
ORa
(95 % CI)
Contros(n = 21,105)
Cases(n = 2,574)
ORa
(95 % CI)
N
(%)
N
(%)
N
(%)
N
(%)
RUNX1
TT/TC
1,480
97.3
1,273
97.5
1.00
2,515
97.7
2,033
96.6
1.00
0.10 (0.77)
(rs2268288)
CC
41
2.7
33
2.5
0.88
(0.55, 1.41)
59
2.3
71
3.4
1.47
(1.03, 2.09)
RUNX3
CC
1,009
66.3
774
59.3
1.00
1,619
63.0
1,301
61.9
1.00
0.01 (0.08)
(rs906296)
CG/GG
512
33.7
532
40.7
1.33
(1.14, 1.55)
952
37.0
802
38.1
1.05
(0.93, 1.18)
RUNX3
GG/GA
1,504
98.9
1,293
99.0
1.00
2,546
99.0
2,068
98.2
1.00
0.21 (1.00)
(rs4478762)
AA
16
1.1
13
1.0
0.98
(0.47, 2.05)
27
1.0
37
1.8
1.71
(1.04, 2.82)
Bold text designates significant associations at the 0.05 level (within strata) after adjustment for multiple comparisons
Odds Ratios adjusted for age, study, and genetic admixture (n = 7,506; missing observations: menopausal status (n = 227)
Interaction p-value (SNP × menopause); Bonferroni p-value for adjustment for multiple comparisons shown in parentheses
The Association of TGF-β signaling pathway genes and breast cancer risk stratified by proportion of Native American ancestry
Gene (SNP)
Genotype
≤0–28 %
29–70 %
71–100 %
p-intb
Case/control
ORa
(95 % CI)
Case/Control
OR a
(95 % CI)
Case/control
ORa
(95 % CI)
RUNX1
CC
1,165/1,229
1.00
1,092/1,285
1.00
390/584
1.00
0.004 (0.04)
(rs7279383)
CG/GG
530/641
0.87
(0.76, 1.00)
288/419
0.82
(0.69, 0.97)
58/50
1.75
(1.17, 2.63)
TGF-β1
CC
772/866
1.00
379/516
1.00
102/141
1.00
0.42 (0.84)
(rs1800469)
CT
692/759
1.01
(0.88, 1.17)
692/854
1.11
(0.94, 1.31)
206/299
0.95
(0.69, 1.30)
TT
1,90/216
0.96
(0.77, 1.20)
295/313
1.29
(1.04, 1.58)
133/193
0.92
(0.65, 1.30)
Odds Ratios adjusted for age and study
Interaction p-value (SNP*admixture); Bonferroni–Holm p-value for multiple comparisons shown in parenthesis; bold text indicates significance after multiple comparisons. Wald p-value within strata adjusted for multiple comparisons by NA ancestry strata (Bonferroni–Holm step-down method), bold text indicates significance (p ≤ 0.05) after multiple comparisons
The association of TGF-P signaling pathway genes and breast cancer risk as defined by ER/PR Phenotypes
Gene (SNP)
Genotype
Controlsa
ER+/PR+
ER+/PR−
ER−/PR+
ER−/PR−
pc
N
N
ORb
(95 % CI)
N
ORb
(95 % CI)
N
ORb
(95 % CI)
N
ORb
(95 % CI)
RUNX1 (rs7279123)
CC
1,935
730
1.00
160
1.00
31
1.00
249
1.00
0.01 (0.06)
CT
1,083
466
1.12
(0.97, 1.29)
65
0.72
(0.53, 0.97)
14
0.83
(0.44, 1.57)
135
0.98
(0.78, 1.22)
TT
184
79
1.10
(0.83, 1.46)
7
0.44
(0.21, 0.96)
0
0.00
(0.00, 0.00)
20
0.88
(0.55, 1.43)
RUNX2 (rs9463090)
GG
2,051
818
1.00
155
1.00
25
1.00
238
1.00
0.01 (0.09)
GA
1,016
410
1.02
(0.88, 1.17)
70
0.93
(0.70, 1.25)
17
1.34
(0.72, 2.50)
130
1.10
(0.87, 1.38)
AA
144
49
0.83
(0.59, 1.16)
8
0.72
(0.35, 1.50)
3
1.81
(0.54, 6.10)
38
2.31
(1.57, 3.39)
RUNX2 (rs12333172)
CC/CT
3,109
1238
1.00
222
1.00
43
1.00
378
1.00
0.01 (0.10)
TT
106
40
0.92
(0.63, 1.33)
11
1.44
(0.76,
2
1.36
(0.32, 5.72)
28
2.12
(1.37, 3.27)
RUNX3 (rs2236850)
TT
1,073
401
1.00
77
1.00
2.73)
11
1.00
105
1.00
0.03 (0.17)
TC
1,526
620
1.08
(0.93, 1.26)
112
1.02
(0.76, 1.38)
15
0.96
(0.44, 2.10)
216
1.44
(1.13, 1.85)
CC
609
257
1.12
(0.93, 1.35)
44
1.00
(0.68, 1.46)
18
2.88
(1.35, 6.16)
83
1.39
(1.02, 1.88)
RUNX3 (rs7517302)
TT
2,664
1035
1.00
191
1.00
32
1.00
324
1.00
0.005 (0.03)
TC/CC
548
242
1.13
(0.96, 1.34)
41
1.05
(0.74, 1.50)
13
2.02
(1.05, 3.88)
82
1.25
(0.96) 1.62)
ER/PR data were compared with 3,214 controls from sites where cases have ER/PR data Mexico data is excluded because they do not have data for ER/PR status (n = 1,810)
Odds ratios (OR) and 95 % confidence intervals (CI) adjusted for age, study, and genetic admixture; Bonferroni-Holms p-value adjustment for multiple comparisons shown in parentheses
Wald-p for overall model, Bonferroni-Holm p-value adjustment for MC shown in parentheses. Wald p-value within strata adjusted for multiple comparisons by admixture strata (Bonferroni-Holm step-down method), bold text indicates significance (p ≤ 0.05) after multiple comparisons